Press release
United Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—Ever
Report available at corporateresponsibility.unither.com SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation
About this update from United Therapeutics Corporation
[{"type":"text","content":"\nReport available at corporateresponsibility.unither.com\n\n SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation (PBC), today announced the release of its 2024 Corporate Responsibility and Public Benefit Report (Report) covering its FY 2023 progress toward its public benefit goals and objectives and summarizing its efforts to advance the interests of patients and other stakeholders.\n\n“Our 2023 financial performance helps set us up for the next revolutionary wave of growth ahead—our organ manufacturing work, which you will read more about in this Report,” said Christopher Causey, Chair of the Nominating and Governance Committee of the United Therapeutics Board of Directors. “Still, we have seen the research demonstrating the connections between patient health and ecosystem health, which is why we maintain our site net zero energy goal for all new construction, where feasible, and invest in groundbreaking green building efforts like our Phase Five LEED Gold certified warehouse in North Carolina. One of the things that I so value about this company is our commitment to walk the talk.”\n\nAs a PBC, United Therapeutics is obligated to report its progress toward its public benefit purpose—to provide a brighter future for patients through the development of novel pharmaceutical therapies, and technologies that expand the availability of transplantable organs. It pursues this purpose alongside its obligations to balance the interests of its other stakeholders, including employees, shareholders, the environment, and the local communities in which it operates.\n\nUnited Therapeutics aligns its environmental, social, and governance (ESG) priorities and performance with its PBC goals. The following are some highlights from this year’s Report:\n\n\nThe company served more than 14,500 patients, including more than 100 benefiting from its centralized ex vivo lung perfusion (EVLP) service in 2023, and more than 400 since service launch;\n\n\nIts patient assistance program has enabled more than 32,000 patients secure access to treatments since 2010;\n\n\nMore than 90 percent of its employees agree, year-after-year since 2018, that United Therapeutics is a Great Place to Work;\n\n\nWith the LEED Gold certification of its Phase Five Warehouse, approxi...